Ipamorelin 10mg

Ipamorelin is a synthetic pentapeptide developed for laboratory research involving growth hormone–related signaling pathways. The ipamorelin peptide acts as a selected agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor. Unlike broader-spectrum growth hormone secretagogues, ipamorelin demonstrates high receptor selectivity, with minimal engagement of other pituitary hormone receptor systems under controlled experimental conditions.

The peptide has an approximate molecular weight of 711 Da. Its pentapeptide structure incorporates non-proteinogenic amino acid residues, which enhance proteolytic resistance and modulate receptor-binding selectivity, supporting predictable behavior during experimental observation and reinforcing its utility as a selective molecular research probe.

This product is supplied as a high-purity lyophilized powder in a sealed vial to support accuracy, stability, and reproducibility across studies. Ipamorelin has been examined in laboratory models focused on growth hormone release dynamics, endocrine signaling specificity, and metabolic regulation.

• GHS-R1a Receptor Agonist with High Selectivity: Enables receptor-specific pharmacology without off-target pituitary hormone activation
• Non-Proteinogenic Pentapeptide Structure: Enhances enzymatic stability and selective GHS-R1a binding
• Dual Signaling Pathway Activation: Engages Gq/PLC-mediated calcium signaling and Gs/cAMP-dependent pathways
• Molecular Probe Utility: Supports discrimination of GHS-R1a–mediated signaling from non-selective secretagogue activity
• High-Purity Research Grade (≥98%): Suitable for analytical and preclinical applications
• Lyophilized 10mg Format: Allows precise reconstitution and experimental flexibility
• Compatible with cell-based assays, tissue studies, and controlled in vivo models
• Commonly selected by laboratories that buy ipamorelin peptide

Ipamorelin is a GHS-R1a agonist that activates dual intracellular signaling pathways to regulate growth hormone release. Upon receptor activation, ipamorelin initiates Gq/phospholipase C (PLC)–dependent signaling, resulting in intracellular calcium mobilization and downstream phosphorylation cascades. In parallel, receptor engagement modulates adenylate cyclase activity, generating cAMP-dependent signaling via Gs-coupled mechanisms.

This coordinated Gq/PLC and Gs/cAMP pathway activation enables regulated growth hormone signaling while preserving high receptor specificity and avoiding activation of unrelated pituitary hormone systems.

In research contexts, ipamorelin is used to interrogate GHS-R1a receptor pharmacology, characterize second-messenger dynamics, and differentiate selective ghrelin-receptor signaling from non-selective secretagogue activity.

1. GHS-R1a Receptor Binding and Selectivity Assays: Characterization of ligand-receptor interactions, binding affinity, and receptor selectivity profiles in biochemical and cell-based systems.
2. Second-Messenger Signaling Analysis: Measurement of intracellular calcium mobilization and cAMP accumulation to assess pathway coupling efficiency and signaling kinetics.
3. Structure–Activity Relationship (SAR) and Comparative Pharmacology Studies: Use as a reference compound to compare selectivity and potency across growth hormone secretagogue peptides.
4. Endocrine-Axis Modeling and Pituitary Hormone Specificity: Investigation of somatotropic signaling without confounding activation of ACTH, prolactin, FSH, or LH pathways.
5. Tissue-Specific Growth Hormone Signaling Models: Studies of bone formation, muscle protein synthesis, and metabolic homeostasis using selective GHS-R1a engagement.

Preclinical Research Summary

• Glucocorticoid-Associated Metabolic and Bone Remodeling Models: Rodent studies examine ipamorelin in glucocorticoid-induced metabolic stress models, assessing osteoblastic markers, bone mineralization, and lean mass composition.
• Pancreatic Islet Function and Glucose Homeostasis Models: Evaluated in isolated islet systems and diabetic animal models to study calcium-dependent insulin secretion and GHS-R1a–mediated signaling dynamics.
• Gastrointestinal Motility and Enteric Signaling Models: Preclinical studies investigate ghrelin-mimetic signaling effects on gastric emptying, intestinal transit, and smooth-muscle contractility.
• Molecular Imaging and Receptor Visualization Research: Ipamorelin has served as a scaffold for fluorescently and radiolabeled derivatives used in receptor-binding visualization and experimental imaging studies.

In published research, ipamorelin has been evaluated across model-specific dosage ranges, adjusted for the experimental model, route of administration, and study duration. Investigations span cell-based receptor assays, isolated tissue preparations, rodent studies, and larger preclinical animal models.

Observed research endpoints include:

• Growth hormone elevation and release kinetics
• Intracellular calcium mobilization
• cAMP accumulation and adenylate cyclase signaling
• Receptor-ligand binding affinity and selectivity
• Downstream phosphorylation and kinase activation
• Osteoblastic activity and bone formation indices
• Pancreatic islet insulin secretion metrics
• Gastrointestinal motility parameters

Researchers who order ipamorelin peptide rely on these endpoints to refine experimental design and compare signaling efficiency across selective secretagogues.

All findings derive exclusively from controlled laboratory and preclinical animal research systems.

Ipamorelin should be stored in its lyophilized form at 2–8°C, protected from light and moisture, to preserve peptide integrity. After reconstitution, solutions should be handled using aseptic laboratory techniques and stored in accordance with institutional protocols, with care taken to minimize repeated freeze–thaw cycles.

This product is intended for use by qualified research professionals in controlled laboratory environments. Proper handling, labeling, and disposal must follow established laboratory safety and compliance standards.

References

https://pubmed.ncbi.nlm.nih.gov/9733495/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7299083/

https://pubmed.ncbi.nlm.nih.gov/9849822/

https://academic.oup.com/endo/article/161/4/bqaa020/5734640

https://pmc.ncbi.nlm.nih.gov/articles/PMC4246099

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.